Comparative Pharmacology
Head-to-head clinical analysis: COREG CR versus ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COREG CR versus ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER.
COREG CR vs ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonselective beta-1, beta-2, and alpha-1 adrenergic receptor antagonist; no intrinsic sympathomimetic activity; reduces myocardial oxygen demand, decreases peripheral vascular resistance, and suppresses renin-angiotensin-aldosterone system.
Selective beta-1 adrenergic receptor antagonist with no intrinsic sympathomimetic activity or membrane stabilizing activity. Reduces heart rate, myocardial contractility, and blood pressure by blocking catecholamine effects at beta-1 receptors predominantly in cardiac tissue.
Initial dose 20 mg orally once daily for patients with heart failure; may increase at 2-week intervals to a target dose of 80 mg once daily.
Loading dose: 500 mcg/kg IV over 1 minute, followed by maintenance infusion of 50 mcg/kg/min IV for 4 minutes. Titrate by 50 mcg/kg/min increments every 4 minutes as needed to maximum of 200 mcg/kg/min. For double-strength (20 mg/mL) formulation, adjust infusion rate accordingly.
None Documented
None Documented
Terminal elimination half-life is 7-10 hours; due to controlled-release formulation, effective half-life is prolonged to support once-daily dosing
Terminal elimination half-life is approximately 9 minutes. Clinical context: ultra-short acting beta-blocker, steady state achieved within 30 minutes.
Renal (16% unchanged, 60% as glucuronide conjugates), biliary/fecal (20%)
Rapid metabolism by red blood cell esterases; metabolites are inactive. Less than 2% excreted unchanged in urine.
Category C
Category A/B
Beta-Blocker
Beta-Blocker